Anticoagulation and bleeding: A pooled analysis of lung cancer trials of the National Cancer Institute of Canada Clinical Trials Group

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 8065-8065
Author(s):  
A. Le Maître ◽  
K. Ding ◽  
F. A. Shepherd ◽  
N. B. Leighl ◽  
A. Arnold ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Trials ◽  
National Cancer Institute ◽  
Pooled Analysis ◽  
Cancer Trials

scholarly journals Anticoagulation and Bleeding: A Pooled Analysis of Lung Cancer Trials of the NCIC Clinical Trials Group

2009 ◽  
Vol 4 (5) ◽  
pp. 586-594 ◽  
Author(s):  
Aurélie Le Maître ◽  
Keyue Ding ◽  
Frances A. Shepherd ◽  
Natasha Leighl ◽  
Andrew Arnold ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Trials ◽  
Pooled Analysis ◽  
Cancer Trials

Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Marimastat After Response to First-Line Chemotherapy in Patients With Small-Cell Lung Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer

2002 ◽  
Vol 20 (22) ◽  
pp. 4434-4439 ◽  
Author(s):  
Frances A. Shepherd ◽  
Giuseppe Giaccone ◽  
Lesley Seymour ◽  
Channa Debruyne ◽  
Andrea Bezjak ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Clinical Trials ◽  
Small Cell Lung Cancer ◽  
National Cancer Institute ◽  
Partial Remission ◽  
Small Cell ◽  
Small Cell Lung ◽  
European Organization

PURPOSE: Increased expression of metalloproteinases is associated with poor prognosis in small-cell lung cancer (SCLC). This trial was undertaken to determine whether adjuvant treatment with the metalloproteinase inhibitor marimastat could prolong survival in responding patients with SCLC after chemotherapy. PATIENTS AND METHODS: SCLC patients in complete or partial remission were eligible. They were stratified by radiotherapy (early, late, or none), stage (extensive or limited), response (complete or partial), and cooperative group (National Cancer Institute of Canada-Clinical Trials Group or European Organization for Research and Treatment of Cancer). They were randomized to receive marimastat 10 mg or placebo orally bid for up to 2 years. RESULTS: There were 532 eligible patients (266 marimastat and 266 placebo). Stage was limited for 279 patients (52%) and extensive for 253 (48%). Best response to induction therapy was complete remission for 176 patients (33%), partial remission for 341 (64%), and 15 patients (3%) had undergone surgical resection. The median time to progression for marimastat patients was 4.3 months compared with 4.4 months for placebo patients (P = .81). Median survivals for marimastat and placebo patients were 9.3 months and 9.7 months, respectively (P = .90) Toxicity was generally limited to musculoskeletal symptoms (18% grade 3/4 for marimastat). Dose modifications for musculoskeletal toxicity were required in 90 patients (33%) on the marimastat arm, and 87 (32%) permanently stopped marimastat because of toxicity. Patients on marimastat had significantly poorer quality of life at 3 and 6 months. CONCLUSION: Treatment with marimastat after induction therapy for SCLC did not result in improved survival and had a negative impact on quality of life.

Clinical Trials and Modern Advertising: The Lung Cancer Trials Flowchart

2006 ◽  
Vol 18 (5) ◽  
pp. 376-377
Author(s):  
R. Stephens ◽  
P. Hoskin
Keyword(s):  
Lung Cancer ◽  
Clinical Trials ◽  
Cancer Trials

scholarly journals Crizotinib versus alectinib for treatment of ALK-positive non-small cell lung cancer: a pooled analysis of the ALEX, ALESIA and J-ALEX clinical trials

2020 ◽  
Author(s):  
Qinghua Zeng ◽  
Xiquan Zhang ◽  
Shan He ◽  
Zhiyong Zhou ◽  
Luping Xia ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Trials ◽  
Adverse Effects ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Pooled Analysis ◽  
Small Cell ◽  
Small Cell Lung ◽  
Anaplastic Lymphoma ◽  
Alk Positive

Abstract Background: Crizotinib and alectinib were the two most commonly used anaplastic lymphoma kinase (ALK) inhibitors for ALK-positive non-small cell lung cancer (NSCLC). We compared their antitumor efficacies and adverse effects based on a pooled analysis of the ALEX, ALESIA and J-ALEX clinical trials.Methods: Seven databases were searched for eligible articles. The primary endpoints included overall survival (OS), progression-free survival (PFS), central nervous system (CNS)-PFS, drug responses and adverse effects (AEs).Results: Three randomized controlled clinical trials (ALEX, ALESIA and J-ALEX) with a total of 7 articles and 697 patients were included. Compared with crizotinib, alectinib exhibited superior efficacy in PFS (HR [hazard ratio]: 0.35, [0.25-0.49], p < 0.00001), OS (HR: 0.66, [0.47-0.92], p = 0.02), CNS-PFS (HR: 0.17, [0.11-0.24], p < 0.00001), duration of response (HR: 0.31, [0.23-0.42], p < 0.00001), objective response rate (ORR) (Risk ratio [RR]: 0.87, [0.80-0.94], p = 0.0003), partial response (PR) (RR: 0.88, [0.81-0.96], p = 0.004), and grade 3-5 AEs (RR: 1.43, [1.09-1.87], p = 0.009). Additionally, the survival advantages of alectinib compared with crizotinib increased with alectinib’s prolongation of survival time. The disease control rate, complete response and total AEs were comparable between the two groups. A greater increase in constipation, nausea, diarrhea, alanine aminotransferase, vomiting, aspartate aminotransferase, peripheral edema, dysgeusia, and visual impairment as well as a greater decrease in appetite and neutrophil count were associated with the crizotinib groupConclusions: In both antitumor efficacy and safety, alectinib appears to be superior to crizotinib for the treatment of ALK-positive NSCLC.

Sign in / Sign up

Export Citation Format

Share Document